Bristol-Myers Squibb Company Ce (CELG-RI) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↑
2.03
+8% vs avg
5yr avg: 1.87
30Y Low1.6·High2.1
P/FCF
↓
0.02
↑+32% vs avg
5yr avg: 0.01
30Y Low0.0·High0.0
P/B Ratio
↓
0.01
↑+76% vs avg
5yr avg: 0.01
30Y Low0.0·High0.0
ROE
↑
40.4%
↓+208% vs avg
5yr avg: 13.1%
30Y Low-39%·High79%
Debt/EBITDA
↑
2.55
+6% vs avg
5yr avg: 2.40
30Y Low0.2·High6.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CELG-RI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bristol-Myers Squibb Company Ce trades at 0.0x earnings, 17% above its 5-year average of 0.0x, sitting at the 67th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 100%. On a free-cash-flow basis, the stock trades at 0.0x P/FCF, 32% above the 5-year average of 0.0x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $225M | $127M | $99M | $187M | $253M | — | — | — | — | — | — |
| Enterprise Value | $39.0B | $38.9B | $41.0B | $30.2B | $31.8B | — | — | — | — | — | — |
| P/E Ratio → | 0.03 | 0.02 | — | 0.02 | 0.04 | — | — | — | — | — | — |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| P/B Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — | — | — | — | — |
| P/FCF | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | — | — | — | — | — | — |
| P/OCF | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CELG-RI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Bristol-Myers Squibb Company Ce's enterprise value stands at 2.0x EBITDA, 8% above its 5-year average of 1.9x. The Healthcare sector median is 14.1x, placing the stock at a 86% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.81 | 0.85 | 0.67 | 0.69 | — | — | — | — | — | — |
| EV / EBITDA | 2.03 | 2.02 | 2.13 | 1.68 | 1.64 | — | — | — | — | — | — |
| EV / EBIT | 2.58 | 2.57 | — | 3.14 | 3.56 | — | — | — | — | — | — |
| EV / FCF | — | 3.03 | 2.94 | 2.39 | 2.67 | — | — | — | — | — | — |
CELG-RI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Bristol-Myers Squibb Company Ce earns an operating margin of 31.4%. Operating margins have expanded from 18.2% to 31.4% over the past 3 years, signaling improving operational efficiency. Return on equity of 40.4% is exceptionally high. ROIC of 19.8% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.9% | 65.9% | 56.8% | 76.2% | 78.0% | 78.6% | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% |
| Operating Margin | 31.4% | 31.4% | 20.0% | 18.2% | 19.7% | 18.4% | 5.1% | 22.6% | 22.7% | 16.6% | 23.4% |
| Net Profit Margin | 14.6% | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.9% | 4.8% | 22.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 40.4% | 40.4% | -39.0% | 26.5% | 18.9% | 18.9% | -20.1% | 10.4% | 38.1% | 7.1% | 29.0% |
| ROA | 7.7% | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.3% | 4.9% | 22.4% | 3.0% | 13.6% |
| ROIC | 19.8% | 19.8% | 12.4% | 10.1% | 10.5% | 9.0% | 2.0% | 8.7% | 26.5% | 15.6% | 18.1% |
| ROCE | 22.3% | 22.3% | 13.6% | 11.1% | 11.2% | 9.1% | 2.1% | 9.8% | 31.1% | 14.1% | 18.7% |
CELG-RI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Bristol-Myers Squibb Company Ce carries a Debt/EBITDA ratio of 2.5x, which is moderately leveraged (22% below the sector average of 3.3x). Net debt stands at $38.8B ($49.0B total debt minus $10.2B cash). Interest coverage of 8.0x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.65 | 2.65 | 3.12 | 1.41 | 1.31 | 1.27 | 1.36 | 0.92 | 0.52 | 0.67 | 0.41 |
| Debt / EBITDA | 2.55 | 2.55 | 2.66 | 2.31 | 2.10 | 2.37 | 4.12 | 6.21 | 1.26 | 1.84 | 1.30 |
| Net Debt / Equity | — | 2.09 | 2.49 | 1.02 | 1.02 | 0.88 | 0.98 | 0.68 | 0.03 | 0.21 | 0.15 |
| Net Debt / EBITDA | 2.01 | 2.01 | 2.12 | 1.67 | 1.63 | 1.64 | 2.95 | 4.59 | 0.08 | 0.59 | 0.48 |
| Debt / FCF | — | 3.02 | 2.93 | 2.37 | 2.64 | 2.08 | 2.79 | 4.87 | 0.09 | 0.60 | 1.51 |
| Interest Coverage | 7.99 | 7.99 | -3.30 | 8.24 | 7.26 | 7.07 | -3.84 | 8.58 | 33.61 | 27.18 | 36.42 |
CELG-RI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.26x means Bristol-Myers Squibb Company Ce can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.43x to 1.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | 1.26 | 1.25 | 1.43 | 1.25 | 1.52 | 1.58 | 1.60 | 5.22 | 1.55 | 1.55 |
| Quick Ratio | 1.14 | 1.14 | 1.15 | 1.31 | 1.14 | 1.43 | 1.47 | 1.37 | 4.51 | 1.43 | 1.41 |
| Cash Ratio | 0.46 | 0.46 | 0.46 | 0.55 | 0.42 | 0.79 | 0.87 | 0.67 | 5.22 | 0.71 | 0.48 |
| Asset Turnover | — | 0.54 | 0.52 | 0.47 | 0.48 | 0.42 | 0.36 | 0.20 | 2.12 | 0.62 | 0.58 |
| Inventory Turnover | 6.11 | 6.11 | 8.16 | 4.02 | 4.33 | 4.74 | 5.68 | 1.88 | 5.48 | 5.20 | 3.99 |
| Days Sales Outstanding | — | 110.01 | 84.12 | 123.79 | 110.21 | 98.49 | 88.42 | 107.29 | 92.98 | 110.68 | 104.14 |
CELG-RI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bristol-Myers Squibb Company Ce returns 100.0% to shareholders annually primarily through dividends. The payout ratio of 71.5% is elevated — while still covered by earnings, there is limited headroom for dividend increases. The earnings yield of 100.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Payout Ratio | 71.5% | 71.5% | — | 59.1% | 73.2% | 62.9% | — | 77.9% | 52.8% | 255.9% | 57.1% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 5536.0% | — | 4288.9% | 2500.0% | — | — | — | — | — | — |
| FCF Yield | 100.0% | 10079.5% | 14037.0% | 6764.5% | 4718.3% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $2.0B | $2.0B | $2.1B | $2.1B | $2.2B | $2.3B | $1.7B | $1.6B | $1.7B | $1.7B |
Peer Comparison
Compare CELG-RI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CELG-RIYou | $225M | 0.0 | 2.0 | 0.0 | 65.9% | 31.4% | 40.4% | 19.8% | 2.5 |
 BMY | $115B | 16.4 | 9.2 | 9.0 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 AZN | $287B | 28.3 | 16.0 | 24.4 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 GILD | $170B | 358.7 | 42.1 | 16.5 | 78.3% | 5.8% | 2.3% | 3.2% | 6.0 |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 VRTX | $109B | 27.9 | 21.7 | 34.1 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See CELG-RI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELG-RI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CELG-RI vs BMY
Side-by-side business, growth, and profitability comparison vs Bristol-Myers Squibb Company.
Start ComparisonCELG-RI — Frequently Asked Questions
Quick answers to the most common questions about buying CELG-RI stock.
What is Bristol-Myers Squibb Company Ce's P/E ratio?
Bristol-Myers Squibb Company Ce's current P/E ratio is 0.0x. The historical average is 0.0x. This places it at the 67th percentile of its historical range.
What is Bristol-Myers Squibb Company Ce's EV/EBITDA?
Bristol-Myers Squibb Company Ce's current EV/EBITDA is 2.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 1.9x.
What is Bristol-Myers Squibb Company Ce's ROE?
Bristol-Myers Squibb Company Ce's return on equity (ROE) is 40.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 26.3%.
Is CELG-RI stock overvalued?
Based on historical data, Bristol-Myers Squibb Company Ce is trading at a P/E of 0.0x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Bristol-Myers Squibb Company Ce's dividend yield?
Bristol-Myers Squibb Company Ce's current dividend yield is 100.00% with a payout ratio of 71.5%.
What are Bristol-Myers Squibb Company Ce's profit margins?
Bristol-Myers Squibb Company Ce has 65.9% gross margin and 31.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Bristol-Myers Squibb Company Ce have?
Bristol-Myers Squibb Company Ce's Debt/EBITDA ratio is 2.5x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.